Investor Presentaiton
Novo Nordisk Annual Report 2023
Equity statement
DKK million
Balance at the beginning of the year
Appropriated from net profit
Appropriated from net profit to net revaluation reserve
Exchange rate adjustments of investments in subsidiaries
Realisation of previously deferred (gains)/losses on cash flow hedges
Deferred gains/(losses) on cash flow hedges incurred during the period
Development costs
Other adjustments
Transactions with owners:
Total dividend for the year
Interim dividends paid during the year
Dividends paid for prior year
Reduction of the B share capital
Purchase of treasury shares
Share-based payments (note 3)
Tax related to restricted stock units
Balance at the end of the year
Proposed appropriation of net profit:
Interim dividend for the year
Final dividend for the year
Appropriated to net revaluation reserve
Transferred to retained earnings
Distribution of net profit
Reserve for cash
Financial statements of the parent company
Net flow hedges and
Share
revaluation
capital
reserve
exchange rate Development
adjustments costs reserve
Retained
earnings
2023
2022
456
17,785
1,045
1,524
62,091
82,901
70,469
33,116
33,116
29,532
8,304
8,304
(2,144)
(1,393)
(1,393)
2,291
(998)
(998)
1,610
1,547
1,547
998
232
(232)
1,284
1,284
976
41,987
41,987
27,950
(13,430)
(13,430)
(9,613)
(18,337)
(18,337)
(15,690)
(5)
5
(29,924)
(29,924)
(24,086)
562
562
433
63
63
175
451
24,696
1,594
1,756
77,185
105,682
82,901
13,430
9,613
28,557
18,337
8,304
(2,144)
33,116
29,532
83,407
55,338
Refer to note 4.3 in the consolidated financial statements for details on the number of
shares, treasury shares and total number of A and B shares in Novo Nordisk A/S.
106View entire presentation